Which action would be the priority when implementing the treatment plan for a patient with diabetic ketoacidosis?

1. 2011 National Diabetes Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2011. [Accessed April 7, 2014]. Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. [Google Scholar]

2. Gosmanov AR, Wall BM. Diabetic ketoacidosis. In: Bope ET, Kellerman RD, editors. Conn’s Current Therapy. Philadelphia, PA: Elsevier Saunders; 2014. 2014. pp. 710–713. [Google Scholar]

3. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–1343. [PMC free article] [PubMed] [Google Scholar]

4. Kitabchi AE, Nyenwe EA. Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am. 2006;35(4):725–751. [PubMed] [Google Scholar]

5. Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care. 2011;34(9):1891–1896. [PMC free article] [PubMed] [Google Scholar]

6. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med. 2006;144(5):350–357. [PubMed] [Google Scholar]

7. Gosmanov AR, Umpierrez GE, Karabell AH, Cuervo R, Thomason DB. Impaired expression and insulin-stimulated phosphorylation of Akt-2 in muscle of obese patients with atypical diabetes. Am J Physiol Endocrinol Metab. 2004;287(1):E8–E15. [PubMed] [Google Scholar]

8. Kitabchi AE, Umpierrez GE, Murphy MB, Kreisberg RA. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(12):2739–2748. [PubMed] [Google Scholar]

9. Sheikh-Ali M, Karon BS, Basu A, et al. Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care. 2008;31(4):643–647. [PubMed] [Google Scholar]

10. Nyenwe EA, Kitabchi AE. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract. 2011;94(3):340–351. [PubMed] [Google Scholar]

11. Caputo DG, Villarejo F, Valle GB, Díaz Aguiar P, Apezteguia CJ. Hydration in diabetic ketoacidosis. What is the effect of the infusion rate? Medicina (B Aires) 1997;57(1):15–20. Spanish. [PubMed] [Google Scholar]

12. Basnet S, Venepalli PK, Andoh J, Verhulst S, Koirala J. Effect of normal saline and half normal saline on serum electrolytes during recovery phase of diabetic ketoacidosis. J Intensive Care Med. 2014;29(1):38–42. [PubMed] [Google Scholar]

13. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med. 1977;297(5):238–241. [PubMed] [Google Scholar]

14. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab. 2008;93(5):1541–1552. [PMC free article] [PubMed] [Google Scholar]

15. Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008;31(11):2081–2085. [PMC free article] [PubMed] [Google Scholar]

16. Goyal N, Miller JB, Sankey SS, Mossallam U. Utility of initial bolus insulin in the treatment of diabetic ketoacidosis. J Emerg Med. 2010;38(4):422–427. [PubMed] [Google Scholar]

17. Rosenthal NR, Barrett EJ. An assessment of insulin action in hyperosmolar hyperglycemic nonketotic diabetic patients. J Clin Endocrinol Metab. 1985;60(3):607–610. [PubMed] [Google Scholar]

18. Maletkovic J, Drexler A. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am. 2013;42(4):677–695. [PubMed] [Google Scholar]

19. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873–1878. [PubMed] [Google Scholar]

20. Umpierrez GE, Latif K, Stoever J, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004;117(5):291–296. [PubMed] [Google Scholar]

21. Ersöz HO, Ukinc K, Köse M, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract. 2006;60(4):429–433. [PubMed] [Google Scholar]

22. Shen T, Braude S. Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Int Med J. 2012;42(12):1347–1350. [PubMed] [Google Scholar]

23. Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1983;57(1):177–180. [PubMed] [Google Scholar]

24. Winter RJ, Harris CJ, Phillips LS, Green OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med. 1979;67(5):897–900. [PubMed] [Google Scholar]

25. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007;18(10):2644–2648. [PubMed] [Google Scholar]

26. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23(2):148–156. [PMC free article] [PubMed] [Google Scholar]

27. Tzamaloukas AH, Ing TS, Siamopoulos KC, et al. Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: review of published reports. J Diabetes Complications. 2008;22(1):29–37. [PubMed] [Google Scholar]

28. Tzamaloukas AH, Rohrscheib M, Ing TS, et al. Serum potassium and acid-base parameters in severe dialysis-associated hyperglycemia treated with insulin therapy. Int J Artif Organs. 2005;28(3):229–236. [PubMed] [Google Scholar]

29. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2(1):162–174. [PubMed] [Google Scholar]

30. Warnock DG. Uremic acidosis. Kidney Int. 1988;34(2):278–287. [PubMed] [Google Scholar]

31. Gutierrez R, Oster JR, Schlessinger FB, Perez GO, Federman DG, Vaamonde CA. Serum sulfate concentration and the anion gap in hemodialysis patients. ASAIO Trans. 1991;37(2):92–96. [PubMed] [Google Scholar]

32. Axelrod L. Response of congestive heart failure to correction of hyperglycemia in the presence of diabetic nephropathy. N Engl J Med. 1975;293(24):1243–1245. [PubMed] [Google Scholar]

33. Tzamaloukas AH, Ing TS, Siamopoulos KC, et al. Pathophysiology and management of fluid and electrolyte disturbances in patients on chronic dialysis with severe hyperglycemia. Semin Dial. 2008;21(5):431–439. [PubMed] [Google Scholar]

34. Montoliu J, Revert L. Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure. Am J Kidney Dis. 1985;5(1):47–48. [PubMed] [Google Scholar]

35. Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012;97(9):3132–3137. [PubMed] [Google Scholar]

36. Savage MW, Dhatariya KK, Kilvert A, et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508–515. [PubMed] [Google Scholar]

37. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Goguen J, Gilbert J. Hyperglycemic emergencies in adults. Can J Diabetes. 2013;37(Suppl 1):S72–S76. [PubMed] [Google Scholar]

38. Bull SV, Douglas IS, Foster M, Albert RK. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. Crit Care Med. 2007;35(1):41–46. [PubMed] [Google Scholar]

39. Waller SL, Delaney S, Strachan MW. Does an integrated care pathway enhance the management of diabetic ketoacidosis? Diabet Med. 2007;24(4):359–363. [PubMed] [Google Scholar]

40. Hara JS, Rahbar AJ, Jeffres MN, Izuora KE. Impact of a hyperglycemic crises protocol. Endocr Pract. 2013;19(6):953–962. [PubMed] [Google Scholar]

41. Devalia B. Adherance to protocol during the acute management of diabetic ketoacidosis: would specialist involvement lead to better outcomes? Int J Clin Pract. 2010;64(11):1580–1582. [PubMed] [Google Scholar]

42. Solá E, Garzón S, García-Torres S, Cubells P, Morillas C, Hernández-Mijares A. Management of diabetic ketoacidosis in a teaching hospital. Acta Diabetol. 2006;43(4):127–130. [PubMed] [Google Scholar]

43. Singh RK, Perros P, Frier BM. Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively? Diabet Med. 1997;14(6):482–486. [PubMed] [Google Scholar]

44. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012;18(Suppl 6):S1–S17. [PubMed] [Google Scholar]

45. Peyrot M, Rubin RR. Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system. Diabetes Technol Ther. 2009;11(1):57–62. [PubMed] [Google Scholar]

46. Wallace TM, Matthews DR. Recent advances in the monitoring and management of diabetic ketoacidosis. QJM. 2004;97(12):773–780. [PubMed] [Google Scholar]


Page 2

Checklist of DKA management milestones

□ Phase I (0–6 h)□ Phase II (6–12 h)□ Phase III (12–24 h)
□ Perform history and physical exam and order initial laboratory studies□ Continue biochemical and clinical monitoring□ Continue biochemical and clinical monitoring
□ Implement monitoring plan (biochemical and clinical)□ Change isotonic fluids to hypotonic fluids if corrected Na normal/high□ Adjust therapy to avoid complications
□ Give intravenous bolus of isotonic fluids□ If glucose is <200–250 mg/dL, add dextrose to intravenous fluids□ Address precipitating factors
□ Start insulin therapy (after fluids started and only if K >3.3 mmol/L)□ Adjust insulin infusion rate as needed□ If DKA resolved, stop intravenous insulin and start subcutaneous insulin
□ Consult diabetes team□ Maintain K at 3.3–5.3 mmol/L range□ Consult diabetes educator